(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 January 2012 (19.01.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/007539 A9

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/4375 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/EP2011/062028

(22) International Filing Date:
14 July 2011 (14.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/364,135 14 July 2010 (14.07.2010) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CHARLTON, Steven, John** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, Sussex RH12 5AB (GB). **LEBLANC, Catherine** [FR/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, Sussex RH12 5AB (GB). **MCKEOWN, Stephen, Carl** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimblehurst Road, Horsham, Sussex RH12 5AB (GB).

(74) Agent: **MUELLER, Philippe**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
1 November 2012

(15) Information about Correction:
see Notice of 1 November 2012

WO 2012/007539 A9

(54) Title: IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

(57) Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.